X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hematology (36) 36
index medicus (32) 32
humans (22) 22
female (18) 18
male (17) 17
life sciences (15) 15
oncology (15) 15
aged (14) 14
middle aged (14) 14
aged, 80 and over (12) 12
leukemia (11) 11
human health and pathology (10) 10
chemotherapy (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
cancer (8) 8
patients (8) 8
rituximab (8) 8
treatment outcome (8) 8
lymphomas (7) 7
myelodysplastic syndromes (7) 7
therapy (7) 7
[ sdv.mhep.hem ] life sciences [q-bio]/human health and pathology/hematology (6) 6
adult (6) 6
diagnosis (6) 6
efficacy (6) 6
geriatry and gerontology (6) 6
medicine & public health (6) 6
transplantation (6) 6
abridged index medicus (5) 5
care and treatment (5) 5
hemic and lymphatic diseases (5) 5
lymphoma (5) 5
medical research (5) 5
medicine, experimental (5) 5
myelodysplastic syndrome (5) 5
survival (5) 5
survival analysis (5) 5
[ sdv.mhep.geg ] life sciences [q-bio]/human health and pathology/geriatry and gerontology (4) 4
[sdv.mhep.hem]life sciences [q-bio]/human health and pathology/hematology (4) 4
acute myeloid leukemia (4) 4
aged patients (4) 4
antineoplastic agents - therapeutic use (4) 4
article (4) 4
bendamustine (4) 4
cll (4) 4
lenalidomide (4) 4
medical prognosis (4) 4
multicenter (4) 4
multiple myeloma (4) 4
myeloproliferative neoplasms (4) 4
non-hodgkins-lymphoma (4) 4
open-label (4) 4
retrospective studies (4) 4
treatment (4) 4
trial (4) 4
1st-line treatment (3) 3
5-azacytidine (3) 3
acute myeloid-leukemia (3) 3
analysis (3) 3
anemia (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
azacitidine (3) 3
azacitidine - therapeutic use (3) 3
bone marrow (3) 3
bortezomib (3) 3
clinical trials (3) 3
combination (3) 3
cyclophosphamide (3) 3
dexamethasone (3) 3
disease-free survival (3) 3
elderly (3) 3
fludarabine (3) 3
hematologic neoplasms - drug therapy (3) 3
hematologic neoplasms - pathology (3) 3
immune system diseases (3) 3
initial therapy (3) 3
kaplan-meier estimate (3) 3
lymphoma, large b-cell, diffuse - drug therapy (3) 3
myeloid leukemia (3) 3
neutropenia (3) 3
phase-ii (3) 3
plus rituximab (3) 3
prednisone - administration & dosage (3) 3
prednisone - adverse effects (3) 3
previously untreated patients (3) 3
prognosis (3) 3
prognostic-factors (3) 3
progression-free survival (3) 3
prospective studies (3) 3
response criteria (3) 3
rituximab - therapeutic use (3) 3
salvage therapy (3) 3
scoring system (3) 3
sezary-syndrome (3) 3
stem cell transplantation (3) 3
stem cells (3) 3
tumors (3) 3
young adult (3) 3
[ sdv ] life sciences [q-bio] (2) 2
[sdv.can]life sciences [q-bio]/cancer (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 04/2017, Volume 129, Issue 15, pp. 2203 - 2203
Journal Article
International Journal of Hematology, ISSN 0925-5710, 7/2018, Volume 108, Issue 1, pp. 3 - 4
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s12185-018-2467-6 
Oncology | Surface antigen expression | Medicine & Public Health | Hematology | IgM subtype | Multiple myeloma | HEMATOLOGY | Immunoglobulins | Immunoglobulin M
Journal Article
The Lancet Oncology, ISSN 1470-2045, 03/2018, Volume 19, Issue 3, pp. 370 - 381
Journal Article
Annals of Hematology, ISSN 0939-5555, 10/2016, Volume 95, Issue 10, pp. 1705 - 1714
Patients aged 80 or over with diffuse large B cell lymphoma (DLBCL) often have comorbidities that increase drug toxicity and prevent the use of otherwise... 
DLBCL | Medicine & Public Health | Hematology | Comorbidity | Oncology | Frailty | R-CVP | Elderly | Performance status | UNITED-STATES | COLONY-STIMULATING FACTOR | RESPONSE CRITERIA | PLUS RITUXIMAB | FOLLOW-UP | COMPREHENSIVE GERIATRIC ASSESSMENT | CHOP CHEMOTHERAPY | PATIENTS OLDER | NON-HODGKINS-LYMPHOMA | DOSE-INTENSITY | HEMATOLOGY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Infection - etiology | Kidney Diseases - chemically induced | Aged, 80 and over | Vincristine - administration & dosage | Female | Retrospective Studies | Doxorubicin - administration & dosage | Rituximab - adverse effects | Severity of Illness Index | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Frail Elderly | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Cardiovascular Diseases - chemically induced | Anthracyclines | Chemotherapy | Analysis | Aged patients | Lymphomas | Cancer | Index Medicus | Life Sciences | Human health and pathology | Geriatry and gerontology
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 2019
Few studies are currently available among elderly patients, justifying the need for better understanding of daily medical practices in terms of use of growth... 
Chemotherapy-induced neutropenia | Primary prophylaxis | Secondary prophylaxis | Elderly patients | Filgrastim
Journal Article
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 06/2017, Volume 56, Issue 6, pp. 635 - 647
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2018, Volume 183, Issue 1, pp. 76 - 86
Journal Article
The Oncologist, ISSN 1083-7159, 09/2018, Volume 23, Issue 9, pp. 1039 - 1053
Peripheral T‐cell lymphoma (PTCL) is a heterogeneous group of clinically aggressive diseases associated with poor outcome. Despite progress in the last several... 
Therapeutic | Drug targeting | New agents | Signaling pathway | Lymphoma | T cell | 1ST-LINE TREATMENT | PROGNOSTIC-FACTORS | MALIGNANT-LYMPHOMAS | BRENTUXIMAB VEDOTIN | OPEN-LABEL | CHOP CHEMOTHERAPY | PREVIOUSLY UNTREATED PATIENTS | PHASE-II TRIAL | ONCOLOGY | UP-FRONT | NON-HODGKIN-LYMPHOMA | Hematologic Malignancies
Journal Article
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 1/2016, Volume 24, Issue 1, pp. 67 - 75
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e18067 - e18067
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e18066 - e18066
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e21614 - e21614
Journal Article